MedTrace Logo

Vaping and Smoking Project in People With Schizophrenia

NCT06944847 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-03-09

No results posted yet for this study

Summary

The proposed research will characterize withdrawal among people with schizophrenia who vape daily compared to people with schizophrenia who smoke combustible cigarettes daily, filling critical gaps in the understanding of electronic nicotine delivery systems (ENDS) dependence and contributing to the development of vaping cessation interventions amongst people with schizophrenia, the leading preventable cause of death in the US.

Conditions

  • Acute Abstinence From Cigarettes vs E-cigarettes (ENDS)

Interventions

BEHAVIORAL

Acute (24-hour) abstinence

Participants will be asked to abstain from all tobacco/nicotine for 24 hours prior to the visit

BEHAVIORAL

Ad libitum smoking/vaping

Participants will be asked to smoke/vape as usual during the 24 hours prior to the visit

Sponsors & Collaborators

  • Roswell Park Cancer Institute

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • State University of New York at Buffalo

    lead OTHER

Principal Investigators

  • Larry Hawk, PhD · University at Buffalo

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-15
Primary Completion
2027-04-01
Completion
2027-04-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06944847 on ClinicalTrials.gov